camlipixant
Small moleculeexperimental
Clinical trial activity
12 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Jul 9, 2018 (NCT03638180)
Timeline
Indications
Mechanism of action
- P2X purinoceptor 3ANTAGONIST
P2X purinoceptor 3 antagonist
- P2X purinoceptor 3INHIBITOR
P2RX3 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CNC(=O)c1cc(F)c(-c2nc3cc(C)ccn3c2C[C@H]2CN(C(=O)OC)CCO2)c(F)c1- Mol. weight
- 458.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095035 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06497517 | Phase 1 | Jul 9, 2024 | GlaxoSmithKline |
| NCT05959447 | Phase 1 | Aug 31, 2023 | GlaxoSmithKline |
| NCT05899829 | Phase 1 | Jun 30, 2023 | GlaxoSmithKline |
| NCT05600777 | Phase 3 | Dec 31, 2022 | GlaxoSmithKline |
| NCT05570539 | Phase 1 | Oct 31, 2022 | Bellus Health Inc |
| NCT05599191 | Phase 3 | Oct 25, 2022 | GlaxoSmithKline |
| NCT06179537 | Phase 1 | Aug 6, 2021 | GlaxoSmithKline |
| NCT04693195 | Phase 2 | Dec 9, 2020 | Bellus Health Inc |
| NCT04678206 | Phase 2 | Dec 7, 2020 | Bellus Health Inc |
| NCT05244759 | Phase 1 | Aug 25, 2020 | Bellus Health Inc |
| NCT03979638 | Phase 2 | Jun 30, 2019 | Bellus Health Inc, University of Manchester |
| NCT03638180 | Phase 1 | Jul 9, 2018 | Bellus Health Inc |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bellus Health Inc | For profit | 6 | 6 | 2 | 2018 |
| GlaxoSmithKline | For profit | 6 | 6 | 2 | 2021 |
| University of Manchester | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1